Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa

Topical therapies for EB are evolving, with more gene-based treatments and anti-inflammatory agents showing potential for improving wounds, reducing pain and overall increasing quality of life. Challenges remain in trial designs, accessibility and long-term safety studies, especially in the context of the heterogeneity of EB. The continued use of standardized outcome measures will affect the future progress of studies, as well as using real-world data. Whilst a definitive cure is unlikely for EB, evolving topical strategies have strong potential in providing control of the disease's symptoms and ultimately can improve long-term outcomes.